Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InModeINMD -0.86%85 ROA % is 9.28% as of Jun. 2026, which is 68% below its 10-year median of 28.77. GuruFocus rates INMD with a GF Score™ of 85/100 and a GF Value™ of $19.34 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, InMode ranks better than 87.34% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. InMode's annualizedNet Income for the quarter that ended in Jun. 2026 was $68.3 Mil.
InMode's average Total Assets over the quarter that ended in Jun. 2026 was $735.6 Mil. Therefore, InMode's annualized ROA % for the quarter that ended in Jun. 2026 was 9.28%.
The historical rank and industry rank for InMode's ROA % or its related term are showing as below:
INMD'
s ROA % Range Over the Past 10 Years
Min: 10.53 Med: 28.77 Max: 42.61
Current: 10.53
During the past 9 years, InMode's highest ROA % was 42.61%. The lowest was 10.53%. And the median was 28.77%.
INMD's ROA % is ranked better than 87.34% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.73
vs INMD: 10.53
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
InMode ROA % Related Terms
InMode ROA % Historical Data
* Premium members only.
The historical data trend for InMode's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InMode's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMode ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InMode's ROA % distribution charts can be found below:
* The bar in red indicates where InMode's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
InMode (INMD) has a ROA % of 9.28% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on InMode and its competitors. This is 68% below median its historical median of 28.77. Over the past decade, InMode's ROA % has ranged from 10.53 to 42.61. According to the industry distribution chart, InMode ranks #108 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 12.7%.
Is InMode's ROA % too high?
InMode's current ROA % of 9.28% is 68% below median its 10-year median of 28.77. Over the past 10 years, this metric has ranged from a low of 10.53 to a high of 42.61. The Medical Devices & Instruments industry median ROA % is 0.73. InMode's value of 9.28% is 1171.2% above this industry median. Based on the distribution chart, InMode ranks #108 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InMode has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InMode's ROA % compare to BVS and PRCT?
According to the Medical Devices & Instruments industry distribution chart, InMode ranks #108 out of 853 companies for ROA %. This places InMode in the top 13% of its industry — outperforming the majority of peers. The industry median ROA % is 0.73. InMode's value of 9.28% is 1171.2% above this benchmark. Historically, InMode's own ROA % has ranged from 10.53 to 42.61 over the past decade. While the company's 10-year median is 28.77 vs. the industry median of 0.73, InMode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.73, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InMode's current ROA % of 9.28% is 1171.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on InMode and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMode's current ROA % is 9.28%, which is 68% below median its own 10-year median of 28.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMode stock overvalued right now?
Based on GuruFocus' analysis, InMode (INMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $19.34, compared to a current price of $14.92 — trading 22.9% below its estimated fair value. The current ROA % is 9.28%, which is 68% below median its 10-year median of 28.77 and 1171.2% above the Medical Devices & Instruments industry median of 0.73. InMode's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For InMode (INMD), the current ROA % is 9.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMode (INMD) Overvalued in 2026?
Based on GuruFocus' analysis, InMode stock appears to be undervalued.
The current stock price of $14.92 is trading 22.9% below its estimated GF Value™ of $19.34.
GuruFocus considers InMode to be Modestly Undervalued.
Key valuation signals for INMD:
ROA %: 9.28% (68% below median its 10-year median of 28.77)
GF Value™: $19.34 vs. price of $14.92 (22.9% below fair value)
Industry Position: 1171.2% above the Medical Devices & Instruments median (#108 of 853)
No single metric tells the full story. See the INMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
85GF Score
Get the complete analysis for INMD
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMD has been successfully added to your 
